

Sarah L Anderson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6425047/publications.pdf>

Version: 2024-02-01

37
papers

826
citations

586496

16
h-index

563245

28
g-index

37
all docs

37
docs citations

37
times ranked

1144
citing authors

#	ARTICLE	IF	CITATIONS
1	Drugs in Context Editorial: Review of 2020 and what lies ahead in therapeutic interventions. <i>Drugs in Context</i> , 2021, 10, 1-5.	1.0	0
2	Retrospective cohort study of statin prescribing for primary prevention among people living with HIV. <i>JRSM Cardiovascular Disease</i> , 2021, 10, 204800402110310.	0.4	1
3	Current and future state of quality metrics and performance indicators in comprehensive medication management for ambulatory care pharmacy practice. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 390-405.	0.5	12
4	Oral semaglutide in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107520.	1.2	39
5	Characterization of clinical pharmacist and hospitalist collaborative relationships. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 1413-1422.	0.5	0
6	Evaluation of a Pharmacist-Led Intervention to Improve Statin Use in Persons with Diabetes. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 910-917.	0.5	7
7	Role of clinical pharmacists and pharmacy support personnel in transitions of care. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 532-545.	0.5	24
8	Bempedoic acid for the treatment of dyslipidemia. <i>Drugs in Context</i> , 2020, 9, 1-9.	1.0	21
9	Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?. <i>Current Cardiology Reports</i> , 2019, 21, 118.	1.3	2
10	Implementation of a Pharmacist-Led Diabetes Management Protocol. <i>American Health and Drug Benefits</i> , 2019, 12, 14-20.	0.5	4
11	Direct Oral Anticoagulant Use in Valvular Heart Disease. <i>Clinical Medicine Insights Therapeutics</i> , 2018, 10, 1179559X1775163.	0.4	3
12	A Review of the Role of the Pharmacist in Heart Failure Transition of Care. <i>Advances in Therapy</i> , 2018, 35, 311-323.	1.3	41
13	Switching basal insulins in type 2 diabetes: practical recommendations for health care providers. <i>Postgraduate Medicine</i> , 2018, 130, 229-238.	0.9	6
14	Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment. <i>Drugs in Context</i> , 2018, 7, 1-7.	1.0	10
15	Role of Aldosterone Receptor Antagonists in Heart Failure With Preserved Ejection Fraction. <i>Clinical Medicine Insights Therapeutics</i> , 2018, 10, 1179559X1877135.	0.4	1
16	Intentional Brodifacoum Ingestion. <i>American Journal of Medicine</i> , 2017, 130, e27-e28.	0.6	10
17	Antihyperglycemic Medications and Cardiovascular Risk Reduction. <i>European Endocrinology</i> , 2017, 13, 86.	0.8	9
18	Novel class of medications, orexin receptor antagonists, in the treatment of insomnia – critical appraisal of suvorexant. <i>Nature and Science of Sleep</i> , 2016, Volume 8, 239-247.	1.4	43

#	ARTICLE	IF	CITATIONS
19	Effects of Medical Marijuana on Migraine Headache Frequency in an Adult Population. <i>Pharmacotherapy</i> , 2016, 36, 505-510.	1.2	71
20	Basal Insulin Use With GLP-1 Receptor Agonists. <i>Diabetes Spectrum</i> , 2016, 29, 152-160.	0.4	34
21	Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 4-17.	1.1	24
22	Response to Comment "Evaluation of Aspirin Use for Primary Prevention in Diabetic Patients". <i>Annals of Pharmacotherapy</i> , 2015, 49, 262-263.	0.9	0
23	Characterization of diastolic dysfunction heart failure following an acute hospitalization for heart failure in an urban, underserved population. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2015, 9, 267-274.	1.0	0
24	Strategies for successfully navigating the pharmacy residency interview process. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, S33-S35.	0.5	6
25	Evaluation of Aspirin Use in Patients With Diabetes Receiving Care in Community Health. <i>Annals of Pharmacotherapy</i> , 2015, 49, 170-177.	0.9	3
26	Suvorexant in insomnia: efficacy, safety and place in therapy. <i>Therapeutic Advances in Drug Safety</i> , 2015, 6, 189-195.	1.0	64
27	Characterization of diabetes risk factors in patients prescribed chronic statin therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2014, 5, 206-211.	1.1	1
28	Quetiapine for insomnia: A review of the literature. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 394-402.	0.5	97
29	Dapagliflozin efficacy and safety: a perspective review. <i>Therapeutic Advances in Drug Safety</i> , 2014, 5, 242-254.	1.0	42
30	Probable Interaction Between Warfarin and Divalproex Sodium. <i>Journal of Pharmacy Technology</i> , 2014, 30, 8-12.	0.5	1
31	Once-weekly albiglutide in the management of type 2 diabetes: patient considerations. <i>Patient Preference and Adherence</i> , 2014, 8, 789.	0.8	16
32	Prevalence of and Factors That Influence Board Certification Among Pharmacy Practice Faculty at United States Colleges and Schools of Pharmacy. <i>Pharmacotherapy</i> , 2013, 33, 105-111.	1.2	13
33	Implementation of a Clinical Pharmacy Specialist-Managed Telephonic Hospital Discharge Follow-Up Program in a Patient-Centered Medical Home. <i>Population Health Management</i> , 2013, 16, 235-241.	0.8	25
34	Histamine-1 receptor antagonism for treatment of insomnia. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2012, 52, e210-e219.	0.7	65
35	Determining predictors of response to exenatide in type 2 diabetes. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2012, 52, 466-471.	0.7	26
36	Dapagliflozin for the Treatment of Type 2 Diabetes. <i>Annals of Pharmacotherapy</i> , 2012, 46, 590-598.	0.9	29

#	ARTICLE	IF	CITATIONS
37	Association of Pancreatitis with Glucagon-Like Peptide-1 Agonist Use. <i>Annals of Pharmacotherapy</i> , 2010, 44, 904-909.	0.9	76